The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...